期刊文献+

替加环素超说明书药物利用评价标准的建立与应用 被引量:4

Establishment and Application of Drug Use Evaluation Criteria of Off-label Drug Use of Tigecycline
下载PDF
导出
摘要 目的:建立替加环素超说明书的药物利用评价(drug use evaluation,DUE)标准,为临床合理用药提供依据。方法:替加环素超说明书DUE标准包括管理指标、用药指征、用药过程和用药结果 4个部分,其中用药指征包括超适应证(占主导)、超剂量、超适应人群和超疗程用药。回顾性分析96例超说明书应用替加环素患者的临床资料,对超说明书用药情况及DUE监测结果进行综合性评价。结果:我院替加环素超说明书用药率为69.57%(96/138);替加环素超说明书DUE标准评价结果显示,对四环素类抗菌药物无过敏、每日至少测量体温2次的符合标准率均为100%,符合标准率较低的为降钙素原监测、肝功能监测及药品不良反应监测等。结论:我院替加环素超说明书用药情况常见,且存在一定问题,应不断完善医院替加环素超说明书合理用药质量保证体系,保证临床用药安全。。 OBJECTIVE: To establish the drug use evaluation( DUE) criteria of off-label drug use of tigecycline,so as to provide basis for the rational drug use in clinic. METHODS: The DUE criteria of off-label drug use of tigecycline were respectively management indicators, medication indication, medication duration and medication results,among which the medication indication included off-indications( leading role),off-dosage,off-population and off-course of treatment. Retrospective analysis was conducted on clinical data of 96 cases of off-label drug use of tigecycline,and comprehensive evaluation was conducted on monitoring results of status of off-label drug use and DUE of off-label drug use of tigecycline. RESULTS: The off-label drug use rate of tigecycline was 69. 57%( 96/138). The DUE criteria of off-label drug use of tigecycline showed that qualified rate toward no allergy to tetracycline antibiotics and taking temperature at least twice a day was 100%; yet monitoring of PCT,liver function and adverse drug reactions had lower qualified rate. CONCLUSIONS: The phenomenon of off-label drug use of tigecycline is common in our hospital,and has some problems. It is necessary to constantly improve the quality assurance system of rational offlabel drug use of tigecycline,so as to ensure safe medication in clinic.
出处 《中国医院用药评价与分析》 2017年第11期1555-1558,共4页 Evaluation and Analysis of Drug-use in Hospitals of China
基金 云南省卫生计生委卫生计生政策研究课题(No.2015YNP06) 云南省教育厅科学研究基金项目(No.2016ZDX022)
关键词 替加环素 超说明书 药物利用评价 回顾性分析 Tigecycline Off-lable DUE Retrospective analysis
  • 相关文献

参考文献4

二级参考文献45

  • 1SOMEYA Y, YAMAGUCHI A, SAWAI T. A novel glycylcycline, 9 - (N, N - Dimethylglycylamido) - 6 - Demethyl - 6 Deoxyte - tracycline, Is neither transported nor recognized by thetransposon Tnl0-encoded metal-tetracycline/H+ Antiporter[J]. Antimicrob Agents Chemother, 1995, 39(1) : 247-249.
  • 2STEIN GE, BABINCHAK T. Tigecycline: an update [J]. Diagn Microbiol Infect Dis, 2013, 75(4): 331-336.
  • 3KEENEY D, RUZIN A, BRADFORD PA. RamA, a transcrip- tional regulator, and AcrAB, an RND- type efflux pump, are associated with decreased susceptibility to Tigecycline inEnterobacter cloacae[J]. Microb Drug Resist, 2007, 13 (1) : 1-6.
  • 4RUZIN A, KEENEY D, BRADFORD PA. AcrAB effiuxpump plays a role in decreased susceptibility to tigecyeline in Morganella morganii[J]. Antimierob Agents Chemother, 2005, 49 (2) : 791-793.
  • 5RUZIN A, VISALLI MA, KEENEY D, et ol. Influence of transcriptional activator RamA on expression of multidrug efflux pump AcrAB and Tigecycline susceptibility in Klebsiella pneumoniae [J]. Antimicrob Agents Chemother, 2005, 49 (3) : 1017-1022.
  • 6VOUILLAMOZ J, MOREILLON P, GIDDEY M, et ol. In vitro activities of tigeeycline combined with other antimicrobials against multiresistant Gram- positive and Gram- negative pathogens[J]. J Antimicrob Chemother, 2008, 61 (2) : 371-374.
  • 7PETERSEN PJ, LABTHAVIKUL P, JONES CH, et al. In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time- kill kinetic analysis[J]. J Antimicrob Chemotherm, 2006, 57 (3): 573 -576.
  • 8MERCIER RC, KENNEDY C, MEADOWS C. Antimicrabial activity of tigecycline (GAR-936) against Enterococcus faecium and Staphylococcus aureus used alone and in combination [J]. Pharmacotherapy, 2002, 22(12): 1517-1523.
  • 9HUANG V, RYBAK MJ. Pharmacodynamics of cefepime alone and in combination with various antimicrobials againstmethi- cillin - resistant Staphylococcus aureus in an in vitro pharmacodynamic infection model[J]. Antimicrob Agents Chemo- ther, 2005, 49(1): 302-308.
  • 10ASLAM S, TRAUTNER BW, RAMANATHAN V, et O1. Combination of tigecycline and N-acetylcysteine reduces biofilm- embedded bacteria on vascular catheters[J]. Antimicrob Agents Chemother, 2007, 51(4) : 1556-1558.

共引文献149

同被引文献33

引证文献4

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部